西洛他唑治疗心动过缓的研究进展

Advance progress in the use of cilostazol to treat bradyarrhythmias

磷酸二酯酶Ⅲ(PDEⅢ)型抑制剂西洛他唑具有抗血小板凝集和血管舒展的作用,临床用于治疗稳定性间歇性跛行,最近研究发现其具有治疗心动过缓的作用。现综述西洛他唑治疗心动过缓的机制,认为西洛他唑对PDEⅢA的抑制是产生治疗心动过缓的主要原因,进而讨论其与PDEⅢ的结合模型,通过结合模型总结了构效关系。

Cilostazol, a selective type Ⅲ phosphodiesterase （PDE Ⅲ） inhibitor, has antiplatelet and vasodilating effects. In clinical, cilostazol is used in the treatment of intermittent claudication （IC）. Recently, cilostazol is reported to has the ability to treat bradyarrhythmias. This article reviews the antibradyarrhythmias mechanism of cliostazol, and consides that inhibiting PDEⅢA is the main reason for treating bradyarrhythmias, then discusses its binding mode with PDEⅢ and structure-function relationship.